Bausch + Lomb (BLCO) Q4 2025 Earnings Transcript

BLCO is transitioning from a “recovery story” into a real leverage story: the important shift is not just that top-line growth is improving, but that the mix is moving toward self-funding franchises with much lower incremental SG&A. That matters because the company now has a visible path to compound EBIT faster than revenue for several years, which should compress skepticism around the durability of the margin program.

The underappreciated second-order effect is capital allocation. As dry eye and premium vision care become bigger profit pools, management can keep launch investment steady while letting gross profit expansion flow through, meaning 2026 is likely to be the inflection year where operating leverage becomes more predictable. If that holds, the market may start valuing BLCO less like a turnaround and more like a niche medtech compounder, which is the key multiple re-rating scenario.

The main risk is not demand, but timing: the earnings cadence is likely to become lumpier as pharmaceutical seasonality grows and as the tax rate normalizes sharply higher. That creates a setup where reported EPS can look noisy even while underlying cash earnings improve, so consensus may underappreciate FCF conversion while overreacting to quarterly volatility. The other latent overhang is float; even if operations continue to execute, that supply issue can cap the speed of multiple expansion for months.

Contrarian read: the market may be too focused on the sustainability of Miebo’s ramp and not enough on the breadth of the platform. The more durable thesis is that BLCO has multiple independently growing drivers, so any one launch disappointment is less damaging than it would have been two years ago. The setup favors buying weakness on tax/seasonality-related selloffs rather than chasing strength after headline guide beats.